Hospital Stocks Face Valuation Reset Risk on Price Caps

Indian hospital stocks face a potential valuation reset as concerns over medicine price controls add to regulatory, cost and competitive pressures. Nomura said the sector’s high valuations leave limited room for margin pressure, after Supreme Court observations on steep mark-ups charged by private hospitals triggered a sharp sell-off. The Supreme Court questioned high mark-ups on medicines and medical consumables, citing a cancer drug with an MRP of ₹27,000 compared with a retailer price of ₹2,700. The court also questioned the practice of requiring patients to purchase medicines through in-house hospital pharmacies and suggested whether a uniform 16% margin could be applied to medicines. Nomura said the immediate earnings impact remains uncertain because the final regulatory framework is not yet clear. However, it highlighted the sector’s sharp re-rating, with the average valuation multiple of Indian hospitals expanding 81% between December 2019 and September 2026, compared with a 30% contraction for international peers. Indian hospital stocks now trade at around a 121% premium to global peers, making them vulnerable if profitability moderates.